Novartis bags Mesoblast's cell therapy, Remestemcel-L for COVID-19 ARDS
The COVID-19 pandemic has put tremendous pressure on scientists to develop a safe and effective vaccine as early as possible. According to the WHO, there are currently more than 100 COVID-19 vaccine candidates under development, with several in the human trial phase. While earlier news came of the efficacy of the potential vaccines from Pfizer and Moderna, this time, it is about a new licensing deal between Novartis and Australia-based Mesoblast.
Novartis has bagged an exclusive worldwide license to develop, commercialize, and manufacture remestemcel-L, Mesoblast’s candidate for acute ...
